Twist Bioscience (TWST) insider tax sale of 1,776 shares

Twist Bioscience Corp (TWST) reported an insider transaction by its President and COO on a Form 4.

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported an insider transaction by its President and COO on a Form 4. On 11/21/2025, the officer sold 1,776 shares of common stock at a price of $26.5035 per share. After this transaction, the officer beneficially owned 332,883 shares directly.

The company explains that these shares were sold solely to cover tax withholding obligations tied to the vesting of restricted stock units. The sale was mandated under the company’s equity incentive plans as a "sell to cover" transaction and is described as not a discretionary trade by the reporting person.

Insider Trade Summary

Net Seller: 1,776 shares

Net Sell 1 txn

Insider Finn Patrick John

Role President and COO

Sold 1,776 shs ($47K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,776	$26.5035	$47K

Holdings After Transaction: Common Stock — 332,883 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

FAQ

What insider transaction did Twist Bioscience (TWST) report in this Form 4?

The filing shows the President and COO of Twist Bioscience (TWST) sold 1,776 shares of common stock on 11/21/2025 in a reported insider transaction.

At what price were the Twist Bioscience (TWST) shares sold in the Form 4 transaction?

The 1,776 shares of Twist Bioscience common stock were sold at a price of $26.5035 per share.

How many Twist Bioscience (TWST) shares does the officer own after this Form 4 sale?

Following the reported transaction, the officer beneficially owned 332,883 shares of Twist Bioscience common stock in direct ownership.

Why did the Twist Bioscience (TWST) insider sell 1,776 shares?

The filing states the 1,776 shares were sold to cover tax withholding obligations related to the vesting of restricted stock units under the company’s equity incentive plans.

Was the Twist Bioscience (TWST) insider sale a discretionary trade?

No. The document explains that the sale was a mandated "sell to cover" transaction required by the company’s equity incentive plans and does not represent a discretionary trade by the reporting person.

Who is the reporting person in the Twist Bioscience (TWST) Form 4 filing?

The reporting person is an officer of Twist Bioscience, serving as President and COO, who reported this transaction on Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/25/2025 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finn Patrick John

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		S		1,776(1)	D	$26.5035	332,883	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.